Skip to main content

Table 2 Demographics and baseline disease characteristics according to baseline SIJ inflammation and structural lesions

From: MRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammation

 

SPARCC SIJ BME

Erosion

Backfill

Fat metaplasia

Ankylosis

≥2 n = 128

>0 n = 58

0 n = 70

>0 n = 26

0 n = 102

>0 n = 14

0 n = 114

>0 n = 3

0 n = 125

<2 n = 55

>0 n = 6

0 n = 49

>0 n = 0

0 n = 55

>0 n = 1

0 n = 54

>0 n = 1

0 n = 54

Age, years

≥2

30.0 (6.1)

33.2 (8.0)

28.9 (6.9)

32.5 (7.3)

32.3 (7.6)

31.7 (7.3)

26.3 (1.2)

31.9 (7.4)

<2

35.3 (12.4)

32.4 (8.4)

─

32.7 (8.8)

40.0

32.6 (8.9)

25.0

32.9 (8.9)

Male, n (%)

≥2

51 (87.9)

34 (48.6)

21 (80.8)

64 (62.8)

12 (85.7)

73 (64.0)

3 (100)

82 (65.6)

<2

3 (50.0)

22 (44.9)

─

25 (45.5)

1 (100)

24 (44.4)

0

25 (46.3)

BMI, kg/m2

≥2

24.6 (3.5)

25.1 (4.5)

24.7 (3.8)

24.9 (4.2)

25.1 (3.1)

24.8 (4.2)

25.9 (4.9)

24.8 (4.1)

<2

26.7 (4.8)

25.3 (5.3)

─

25.4 (5.2)

30.1

25.4 (5.3)

17.3

25.6 (5.2)

Symptom duration, years

≥2

2.5 (2.3)

2.7 (1.5)

3.0 (2.9)

2.5 (1.5)

3.2 (1.7)

2.5 (1.9)

4.0 (1.2)

2.5 (1.9)

<2

2.4 (1.5)

2.0 (1.4)

─

2.0 (1.4)

0.3

2.0 (1.4)

4.0

2.0 (1.4)

HLA-B27 positive, n (%)

≥2

50 (86.2)

47 (67.1)

25 (96.2)

72 (70.6)

12 (85.7)

85 (74.6)

3 (100)

94 (75.2)

<2

5 (83.3)

30 (61.2)

─

35 (63.6)

1 (100)

34 (63.0)

1 (100)

34 (63.0)

Anterior uveitis, n (%)

≥2

5 (8.6)

8 (11.4)

1 (3.9)

12 (11.8)

2 (14.3)

11 (9.7)

1 (33.3)

12 (9.6)

<2

0

1 (2.0)

─

1 (1.8)

0

1 (1.9)

0

1 (1.9)

IBD, n (%)

≥2

0

0

0

0

0

0

0

0

<2

0

1 (2.0)

─

1 (1.8)

0

1 (1.9)

0

1 (1.9)

PsO, n (%)

≥2

6 (10.3)

12 (17.1)

2 (7.7)

16 (15.7)

3 (21.4)

15 (13.2)

0

18 (14.4)

<2

0

5 (10.2)

─

5 (9.1)

0

3 (5.6)

0

5 (9.3)

PsO family history, n (%)

≥2

4 (6.9)

1 (1.4)

0

5 (4.9)

1 (7.1)

4 (3.5)

0

5 (4.0)

<2

0

3 (6.1)

─

3 (5.5)

0

3 (5.6)

0

3 (5.6)

ASDAS-CRP

≥2

3.0 (1.1)

3.1 (0.9)

3.2 (1.1)

3.0 (1.0)

2.7 (0.7)

3.1 (1.0)

3.1 (0.1)

3.1 (1.0)

<2

2.4 (1.3)

2.8 (0.8)

─

2.8 (0.9)

0.7

2.8 (0.8)

1.8

2.8 (0.9)

CRP, mg/l

≥2

7.6 (9.7)

7.7 (13.9)

8.6 (9.5)

7.4 (12.8)

4.0 (4.1)

8.1 (12.8)

2.8 (2.2)

7.7 (12.3)

<2

5.8 (10.0)

4.9 (7.0)

─

5.0 (7.2)

1.3

5.1 (7.3)

2.2

5.1 (7.3)

BASDAI, 0–10

≥2

5.6 (2.0)

6.4 (1.7)

5.9 (2.3)

6.1 (1.7)

5.4 (1.9)

6.1 (1.8)

6.8 (1.2)

6.0 (1.9)

<2

4.7 (2.5)

5.9 (1.6)

─

5.8 (1.7)

0.4

5.9 (1.6)

3.5

5.8 (1.7)

BASFI, 0–10 cm VAS

≥2

3.6 (2.6)

4.5 (2.5)

3.7 (2.8)

4.2 (2.5)

3.6 (2.0)

4.2 (2.6)

4.5 (0.7)

4.1 (2.6)

<2

3.0 (1.6)

3.9 (2.2)

─

3.8 (2.1)

0.5

3.8 (2.1)

2.9

3.8 (2.2)

BASMI, 0–10

≥2

1.1 (1.3)

1.3 (1.4)

1.1 (1.5)

1.2 (1.3)

0.9 (1.1)

1.3 (1.4)

1.3 (2.2)

1.2 (1.3)

<2

1.2 (1.0)

1.4 (1.3)

─

1.3 (1.3)

0

1.4 (1.3)

1.3

1.3 (1.3)

SPARCC spine score, 23-DVU, 0–414

≥2

7.5 (12.8)

4.0 (5.7)

9.1 (16.1)

4.6 (7.1)

5.6 (7.7)

5.5 (9.9)

11.7 (14.9)

5.4 (9.6)

<2

2.8 (4.2)

2.5 (3.9)

─

2.5 (3.9)

3.5

2.5 (3.9)

1.0

2.5 (3.9)

  1. Values are mean (standard deviation) unless stated otherwise. ASDAS-CRP Ankylosing Spondylitis Disease Activity Score based on C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, BME bone marrow edema, BMI body mass index, CRP C-reactive protein, DVU discovertebral units, HLA human leukocyte antigen, IBD inflammatory bowel disease, PsO psoriasis, SIJ sacroiliac joint, SPARCC Spondyloarthritis Research Consortium of Canada, VAS visual analog scale
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us